A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Conclusions The recommended dose of BEZ235 administered BID as an oral sachet formulation is 300 mg BID. Toxicities seen have been reported for other dual PI3K/mTOR inhibitors.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoid Tumor | Colorectal Cancer | Drugs & Pharmacology | Endometrial Cancer | Investigational New Drugs | Melanoma | Oral Cancer | Pancreas | Skin Cancer | Study | Thrombocytopenia | Toxicology